CN101505596B - 纳米级类胡萝卜素环糊精复合物 - Google Patents
纳米级类胡萝卜素环糊精复合物 Download PDFInfo
- Publication number
- CN101505596B CN101505596B CN2006800372474A CN200680037247A CN101505596B CN 101505596 B CN101505596 B CN 101505596B CN 2006800372474 A CN2006800372474 A CN 2006800372474A CN 200680037247 A CN200680037247 A CN 200680037247A CN 101505596 B CN101505596 B CN 101505596B
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- carotenoid
- mixture
- composition
- fish oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000021466 carotenoid Nutrition 0.000 title claims abstract description 93
- -1 carotenoid cyclodextrin complexes Chemical class 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 claims abstract description 107
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 78
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 61
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 44
- 235000016709 nutrition Nutrition 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 235000021323 fish oil Nutrition 0.000 claims description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 239000002002 slurry Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 13
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 13
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 8
- 235000013734 beta-carotene Nutrition 0.000 claims description 8
- 239000011648 beta-carotene Substances 0.000 claims description 8
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 8
- 229960002747 betacarotene Drugs 0.000 claims description 8
- 239000007766 cera flava Substances 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 8
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 8
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 7
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 7
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 7
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 7
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 7
- 235000013793 astaxanthin Nutrition 0.000 claims description 7
- 239000001168 astaxanthin Substances 0.000 claims description 7
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 7
- 229940022405 astaxanthin Drugs 0.000 claims description 7
- 235000012661 lycopene Nutrition 0.000 claims description 7
- 239000001751 lycopene Substances 0.000 claims description 7
- 229960004999 lycopene Drugs 0.000 claims description 7
- 230000035764 nutrition Effects 0.000 claims description 7
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 7
- 235000010930 zeaxanthin Nutrition 0.000 claims description 7
- 239000001775 zeaxanthin Substances 0.000 claims description 7
- 229940043269 zeaxanthin Drugs 0.000 claims description 7
- 238000003801 milling Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000008398 formation water Substances 0.000 claims description 2
- 235000005473 carotenes Nutrition 0.000 claims 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000011160 research Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000235553 Blakeslea trispora Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000168517 Haematococcus lacustris Species 0.000 description 1
- 244000182264 Lucuma nervosa Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G23/00—Compounds of titanium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明提供了制备用于增强营养剂吸收的纳米级营养制剂的方法。该方法包括将环糊精与类胡萝卜素复合并将该复合物不经过收集、分离和干燥的中间步骤而掺入营养补充剂中。
Description
本申请要求于2005年10月5日提交的申请号为60/724,051的美国临时专利申请的优先权。
发明领域
本发明涉及通过提供含有类胡萝卜素的营养补充制剂来提高其生物利用度的组合物和相关方法。本发明也相应地涉及化学、食品科学、生物学和营养学的领域。
发明背景
类胡萝卜素是一类有色的、高脂溶性的植物色素,它们在营养和健康方面的益处是众所周知的。与类胡萝卜素有关的益处包括抗氧化活性和向维生素A的转化。研究表明饮食中较多地摄入类胡萝卜素对某些发展中的癌症、黄斑变性、白内障、心脏病和其它与氧化或自由基损伤有关联的健康问题有防护作用。鉴于类胡萝卜素这些显著的和预期的健康益处,营养品公司已经迅速地把含有类胡萝卜素的产品投入市场。遗憾的是,类胡萝卜素在肠液内不易溶解,因而被人体吸收的通常很少。
因此,人们一直在寻找提高类胡萝卜素及其它营养素的吸收和生物利用度的方法和体系。
发明概述
相应地,本发明提供了主要通过特定的加工技术来提高营养素,特别是类胡萝卜素的生物利用度的方法和组合物。
本发明的一个实施方案中包括了制备含有类胡萝卜素的营养补充剂的方法。所述方法包括:将一定量的环糊精与水在50℃混合,形成水/环糊精的浆体,将一定量的至少一种类胡萝卜素掺到该水/环糊精浆体中,得到包括类胡萝卜素-环糊精复合物的预混合成分。然后将预混合成分抽真空并充分混合至少1小时,在真空下将未干燥的预混合成分与其它营养成分于40~45℃进行混合,形成最终混合物,碾磨最终混合物并将其装入胶囊。
一方面,本发明中的环糊精是指γ-环糊精。另一方面,本发明中的至少一种类胡萝卜素选自虾青素、番茄红素、玉米黄素、β-胡萝卜素以及它们的组合。另一方面,本发明中的其它营养成分包括鱼油、蜂蜡、维生素A、维生素E、叶黄素、柠檬烯、磷虾油以及它们的组合,可以掺入该组合物中。
本发明中制备含有类胡萝卜素的营养补充剂的另一个实施方案包括在混合装置中将一定量的水加热至50℃,将一定量的环糊精与水混合形成水/环糊精浆体,再掺入一定量的至少一种类胡萝卜素到水/环糊精浆体中,形成包括类胡萝卜素环糊精复合物的预混合成分,在单独的混合容器中将预混合成分抽真空并充分混合至少1小时,并在60℃时加入一定量的鱼油,充分混合后形成鱼油混合物,然后冷却至40~45℃,将未干燥的预混合成分与鱼油/蜂蜡混合物在真空下于40~45℃进行混合,形成最终混合物,任选地将其它营养补充剂掺入最终混合物中,将最终混合物冷却至25~28℃,在真空下碾磨最终混合物以缩小颗粒尺寸,将碾磨过的混合物装入胶囊。
发明详述
定义
在本发明的说明书及权利要求书中,所使用的以下术语按照下述定义。
除非上下文另有清楚的说明,“一个”和“一种”都包括其复数形式。因此,例如文中所述的含有“一种环糊精成分”的营养补充剂,包括“一种或多种环糊精成分”;文中所述的“一种”类胡萝卜素,包括“一种或多种类胡萝卜素”。
如本文所用的“个体”是指由于施用了本发明的营养补充剂或方法而可能受益的哺乳动物。个体的实例包括人类,也包括其它动物如马、猪、牛、狗、猫、兔及水生哺乳动物。
如本文所用的术语“制剂”和“组合物”是可互换使用的,指两种或更多种的化合物、元素或分子的混合物。
如本文所用的“单次剂量”,是指能够向个体递送所希望的量的类胡萝卜素的一个或多个胶囊递送单位。
如本文所用的“有效量”和“足够量”是可互换使用的,是指包含于可咀嚼的组合物时,足以产生预期的成分效应或生理效应的组分的量。例如,“足够量”的类胡萝卜素提取物是指产生营养作用所需的最小剂量。另外,“治疗有效量”指的是足以达到所期望的生理作用的类胡萝卜素的量。有效量可以在药学、营养品、中草药、化妆品和医学领域的常规技术范围内确定。参见,例如Meiner和Tonascia,“临床试验:设计、实施和分析”,流行病学和生物统计学专题论文(Monographs in Epidemiologyand Biostatistics),Vol.8(1986),其引入本文用作参考。
术语“混合的”指的是可溶解、分散或混悬于载体中的药物和/或强化剂。某些情况下,药物可以均匀地混合在载体中。
如本文所用,为了方便,可以将许多项目、结构元素、组成元素和/或物质列于一份共同的清单中。但是,这些清单应当进行解释,就象清单中各成员作为单独的和唯一的成员分别进行确认一样。因此,如果没有相反的指示,根据其通常含义,这类清单中应当没有某个成员解释为该清单中任何其他成员的实际的等价物。
文中的浓度、数量及其它数据可以表示或表现为一种范围格式。应当理解使用这种范围格式仅仅为了方便和简洁,因此其应当灵活地解释为不仅包括以范围的界限形式明确陈述的数值,也包括包含在所述范围内的所有的单个数值或子界,就象每个数值和子界均被明确陈述一样。例如,“约1-5”的数值范围应当解释为不仅包括约1-5的明确陈述的值,还包括在所述范围内的各个数值和子界。因此,单个数值如2、3、4以及子界如1-3、2-4、3-5等都包含于该数值范围内。
同样的原则也适用于陈述只有一个数值的范围。而且,对于所描述的范围或特征的宽度方面也采用这种解释。
发明详述
本发明包括制备含有类胡萝卜素的营养补充剂的方法,所述方法包括形成类胡萝卜素环糊精复合物。在营养领域,类胡萝卜素对健康的各种益处是众所周知的。本发明提供了制备容易吸收的含有类胡萝卜素的营养补充剂的方法,该方法易于操作,耗时少成本低,得到的产物中所含类胡萝卜素既高度稳定又是生物易于吸收利用的。
在营养补充剂领域中众所周知,类胡萝卜素在肠液中的溶解度较低。较低的溶解度导致类胡萝卜素的吸收差或不易摄入循环系统。导致类胡萝卜素吸收差的另一个因素是类胡萝卜素有容易聚集成不易消化和吸收的大颗粒的趋势。环糊精能够包裹不易溶解的化合物,提高其溶解性,抑制其经常发生的聚集。由于颗粒尺寸极小,较小的被包裹的化合物通常指的是纳米颗粒。
本发明提供了制备含有类胡萝卜素环糊精复合物的营养补充剂的流线型的方法。特别是提供了制备类胡萝卜素环糊精复合物以及随后不经过收集、分离、干燥的中间步骤直接将其与营养补充剂混合的方法。由于类胡萝卜素-环糊精复合物可以直接掺入营养补充剂而没有中间步骤,这就降低了成本。
本发明的方法包括将一定量的环糊精和水混合形成环糊精浆体。加工浆体优选的温度为50℃。本发明中可以使用的各种类型的环糊精及其衍生物包括α-环糊精、γ-环糊精及β-环糊精。在一个实施方案中使用的环糊精是γ-环糊精。另一个实施方案中使用的环糊精是γ-环糊精和β-环糊精的混合物。环糊精和水的混合物应当混合约20分钟或直至观察到焦糖色。水的作用是水合环糊精。水合的环糊精能与类胡萝卜素更好的混合。一旦环糊精浆体形成,将类胡萝卜素掺入其中。类胡萝卜素/环糊精混合物应当在约40℃-50℃下持续混匀最少1小时。在高剪切力下混合类胡萝卜素/环糊精混合物可增强或提高反应速率,并由此提高类胡萝卜素环糊精复合物的形成速率。然而,较低混合速度产生的低剪切力也可用于有效地形成类胡萝卜素环糊精复合物。
本发明使用的类胡萝卜素可以包括任何一种本领域内已知的对健康有积极作用的类胡萝卜素。用于本发明的优选的类胡萝卜素为虾青素、番茄红素、玉米黄素、β-胡萝卜素、叶黄素及其混合物。条件允许的话,优选将含有类胡萝卜素的本发明的组合物抽真空以减缓或抑制类胡萝卜素的降解。另一种维持类胡萝卜素稳定性的可接受的方法是将含有类胡萝卜素的混合物置于氮气下。
当类胡萝卜素/环糊精组分混合时,类胡萝卜素-环糊精复合物开始从溶液中沉淀出来,使溶液变得更粘稠。这种粘度的增加可用作类胡萝卜素环糊精复合物成功形成的指示剂。传统的类胡萝卜素环糊精复合物的制备方法中,沉淀的复合物在此时被收集、分离和干燥。这样做会导致原先存在于环糊精浆体中的水分丢失。在本发明方法中,包含水的复合物维持在预混合的浆体状态。本发明的加工方法省去了干燥过程,能够减少相关过程的时间和成本。
类胡萝卜素-环糊精复合物形成后,预混合浆体可以接着与其它的营养成分在40℃-45℃形成最终混合物。将最终混合物充分混合至少20分钟。本发明中其它的营养成分的实例包括但不限于维生素A、维生素E、叶黄素、鱼油、柠檬烯、蜂蜡以及它们的组合。最终混合物优选与鱼油混合。本发明可使用任何类型的本领域技术人员熟知的鱼油。用于本发明的虾油也包括在鱼油内。
除了鱼油固有的健康益处外,在预混合浆体中加入鱼油有助于稳定和溶解其中游离的类胡萝卜素,进而提高游离的和复合的类胡萝卜素的生物利用度。当本发明的类胡萝卜素-环糊精复合物与最小量的鱼油共同施用时,已经确定类胡萝卜素的生物利用度高于单独的类胡萝卜素-环糊精复合物。不受理论限制的话,相信类胡萝卜素生物利用度的提高,至少部分是由于鱼油刺激肠道中的脂肪酶因而促进类胡萝卜素的吸收。一个优选的实施方案中鱼油为最终混合物的约70重量%-90重量%。另一个实施方案中鱼油为最终混合物的约75重量%-85重量%。当最终混合物包含其它营养成分,特别是容易氧化的成分如维生素A和维生素E时,鱼油也对它们有稳定和保护作用。
一旦最终混合物组分完成,将其碾磨以确保得到较小颗粒尺寸的复合的类胡萝卜素。将最终混合物碾磨后可直接装入胶囊或在氮气条件下储存于密闭容器中。在本发明优选的一个实施方案中,将最终混合物装入软明胶胶囊中。打算将按照本发明的方法制备的组合物向个体递送,以提供治疗有效量的类胡萝卜素。根据本发明组合物中类胡萝卜素的浓度,本领域技术人员可以容易地确定所用的量。
除了所述的方法外,本发明还提供了组合物以及提高类胡萝卜素生物利用度的相关方法。特别是已经发现如上所述最终混合物成分中包含鱼油时,类胡萝卜素的生物利用度出乎意料地得到提高,高于仅含有类胡萝卜素/环糊精复合物或鱼油/类胡萝卜素混合物的生物利用度。如上文所讨论,相信生物利用度出乎意料的提高,至少部分是由于鱼油刺激肠道中的脂肪酶因而促进了类胡萝卜素的吸收。
以下给出的实施例是制备本发明含有类胡萝卜素的营养补充剂的一个实施方案的例子。尽管其加工条件和组分可能是优选的,但不意味着对本发明有任何限制。
实施例1
按以下步骤制备含有稳定的类胡萝卜素的营养补充剂。
1.将5.640kg水加入到混合器中并加热至50℃。在加入环糊精前确认温度。
2.从混合器的容器中取下混合器的刀片,并加入4.070kg的γ-环糊精(Cavamax V Wacker Biochem),最初用手混匀,然后机械混合至少30分钟或直至环糊精/水的浆体形成。浆体呈焦糖色。
3.根据下表所示的量,加入下列类胡萝卜素:
类胡萝卜素 | 活性(%或IU/mg) | kg |
β-胡萝卜素(30%悬液,三孢布拉氏霉(B.trispora)) | 500.00IU | 0.273 |
β-胡萝卜素(Caromin 13%b 6.5%a;油;棕榈果) | 13.000% | 0.689 |
虾青素,5%OIL BioAstin(雨生红球藻(H.pluvialis)) | 5.000% | 0.224 |
番茄红素(20%油悬液)LycoVit合成 | 20.000% | 0.560 |
玉米黄素(20%悬液) | 20.000% | 0.056 |
4.将混合容器抽真空,混合物在4-45℃以低速(9.6rpm)混合至少1小时,形成类胡萝卜素环糊精复合物。(注意:当类胡萝卜素与环糊精发生反应时化合物将会沉淀,并且混合物粘度的增加指示络合反应成功。)
5.类胡萝卜素环糊精复合物在混合容器中混合至少1小时后,立即移入含有鱼油/蜂蜡混合物的主混合器中。所述鱼油/蜂蜡混合物通过将约6.1kg蜂蜡与73.2kg鱼油加入混合容器并在60℃混合直至充分混匀来制备。将此组分冷却至40-45℃之后加入类胡萝卜素环糊精复合物。可用少量的鱼油/蜂蜡组分将类胡萝卜素-环糊精复合物冲洗到主混合器中。
6.可以将其它成分加入混合器。根据下表所示的量加入各组分:
组分 | 活力(%或IU/mg) | kg |
维生素A(棕榈酸盐,液态1,700USP) | 1600.0IU | 0.043 |
维生素E(d-α-生育酚1490油) | 1.430IU | 2.988 |
维生素E,60%g-t,6.8%a-t,1.4%b-t,MTS-90G Oil | 60.000% | 2.671 |
维生素E 生育三烯酚类(50%E&TT,棕榈果油) | 38.000% | 0.028 |
叶黄素(酯,Xangold,油悬液,15%) | 15.000% | 0.298 |
虾油 | 100.000% | 2.035 |
D-柠檬烯(液态) | 95.000% | 1.071 |
7.加入类胡萝卜素/环糊精复合物和其它成分后,将主混合器抽真空,在20-45℃采用高剪切力混合20分钟。然后将混合物冷却至25-28℃,移出混合器,碾磨以减小颗粒尺寸。
8.碾磨后可以将混合物储存于在氮气条件的密封容器中或立即封入胶囊。所用胶囊为软明胶胶囊。每个软明胶胶囊含有大约1.2克经碾磨的最终组合物。
实施例2
进行了一项关于个体皮肤的类胡萝卜素得分(SCS)的研究,来确定权利要求1中的组合物的效果。该研究包括使用拉曼光谱测定法对历时18星期服用实施例1的组合物的实验组与安慰剂组的皮肤类胡萝卜素得分变化进行评估。
52例年龄在18到65岁的受试者获得资格参与该研究。使用饮食频率和健康史的调查问卷作为筛选标准,并使用Pharmanex BiophotonicScanner光电扫描仪来评估皮肤的类胡萝卜素水平。服用抗氧化补充剂者、阳光暴晒过多或使用日光浴床者、孕妇或使用不需阳光而使皮肤变深色的产品的个体均排除在研究之外。所有研究对象均为健康的非吸烟者,具有典型的美国饮食习惯,即水果和蔬菜日消费少于5份,并且其拉曼密度得分基线在13,000和35,000个拉曼密度读数之间。在研究期间,要求参与者维持其饮食和锻炼习惯。符合研究条件的受试者(n=52)以双盲的方式随机分配到两组,即实施例1的组合物组(n=27)或安慰剂组(n=25)的其中一组。
分别给予受试者各自的胶囊,即安慰剂或实施例1的组合物。要求他们一天服用两次(一次在早餐时,一次在晚餐时)。实施例1组的参加者的剂量包括一天两次、每次2粒软胶囊。安慰剂组也是一天两次、每次2粒软胶囊,但其所含的是ω-3脂肪酸而不是类胡萝卜素。
研究结果显示皮肤的类胡萝卜素得分有出乎意料的增加。特别是18星期后,与安慰剂组几乎没有变化的结果相比,服用实施例1的组合物的参加者平均升高了17,757个拉曼密度计数。在18星期的研究中,类胡萝卜素扫描得分持续升高而没有明显的平台效应。
上述实施例是对本发明原理的一个或多个特别应用的说明,对于本领域普通技术人员而言显而易见,在不需要创造性劳动和不偏离本发明的原理和概念下,可以对本发明实施的形式、用途、细节方面进行各种修饰。因此,本发明除了受到下述的权利要求书的限制外,不受其他限制。
Claims (27)
1.制备含有类胡萝卜素的营养补充剂的方法,包括:
a)在50℃将一定量的环糊精和水混合形成水/环糊精浆体,
b)将一定量的至少一种类胡萝卜素加入到水/环糊精浆体中,形成含有环糊精类胡萝卜素复合物的预混合成分,
c)将预混合成分抽真空并将其充分混合至少1小时,
d)在真空下将未干燥的预混合成分与包括鱼油的其它营养组分在约40℃-45℃混合形成最终混合物,
e)在真空下碾磨最终混合物,
f)将碾磨好的最终混合物装入胶囊。
2.如权利要求1所述的方法,其中所述环糊精是γ-环糊精。
3.如权利要求1所述的方法,其中所述环糊精是γ-环糊精和β-环糊精的组合。
4.如权利要求1所述的方法,其中至少一种类胡萝卜素选自虾青素、番茄红素、玉米黄素、β-胡萝卜素、叶黄素以及它们的混合物。
5.如权利要求1所述的方法,其中所述其它营养组分还包括选自蜂蜡、维生素A、维生素E、D-柠檬烯以及它们的混合物的成分。
6.如权利要求1所述的方法,其中鱼油为最终混合物的70重量%到90重量%。
7.如权利要求6所述的方法,其中鱼油为最终混合物的75重量%到85重量%。
8.如权利要求1所述的方法,其中将碾磨后的最终混合物装入软明胶胶囊中。
9.制备含有类胡萝卜素的营养补充剂的方法,包括:
a)在混合装置中将一定量的水加热至50℃,
b)将一定量的环糊精和水混合,形成水/环糊精浆体,
c)将一定量的至少一种类胡萝卜素混入水/环糊精浆体中形成含有环糊精类胡萝卜素复合物的预混合成分,
d)将预混合成分抽真空并将其充分混合至少1小时,
e)在单独的混合容器中,将一定量的鱼油加温至40℃-45℃,
f)在真空下将未干燥的预混合成分在约40℃-45℃与鱼油混合形成最终混合物,
g)任选地将其它营养成分加入至最终混合物,
h)将最终混合物冷却至25℃-28℃,
i)在真空下碾磨最终混合物以减小颗粒尺寸,
j)将碾磨好的最终混合物装入胶囊。
10.如权利要求9所述的方法,其中所述环糊精是γ-环糊精。
11.如权利要求9所述的方法,其中所述环糊精是γ-环糊精和β-环糊精的组合。
12.如权利要求9所述的方法,其中至少一种类胡萝卜素选自虾青素、番茄红素、玉米黄素、β-胡萝卜素、叶黄素以及它们的混合物。
13.如权利要求9所述的方法,其中所述其它营养组分选自蜂蜡、维生素A、维生素E、D-柠檬烯以及它们的混合物。
14.含有类胡萝卜素的组合物,其包括:
至少一种类胡萝卜素;
环糊精;和
鱼油,其中鱼油为组合物重量的70重量%到90重量%。
15.如权利要求14所述的组合物,其中所述环糊精是γ-环糊精。
16.如权利要求14所述的组合物,其中所述环糊精是γ-环糊精和β-环糊精的组合。
17.如权利要求14所述的组合物,其中至少一种类胡萝卜素选自虾青素、番茄红素、玉米黄素、β-胡萝卜素、叶黄素以及它们的混合物。
18.如权利要求14所述的组合物,其进一步包括选自蜂蜡、维生素A、维生素E、D-柠檬烯及其混合物的其它营养成分。
19.如权利要求14所述的组合物,其中鱼油为组合物重量的70重量%到90重量%。
20.如权利要求14所述的组合物,其中至少一种类胡萝卜素与环糊精复合。
21.提高类胡萝卜素生物利用度的方法,包括:
将类胡萝卜素与环糊精和鱼油的组合产品共同施用于需要它的个体。
22.如权利要求21所述的方法,其中类胡萝卜素和环糊精是复合在一起的。
23.如权利要求21所述的方法,其中所述环糊精是γ-环糊精。
24.如权利要求21所述的方法,其中所述环糊精是γ-环糊精和β-环糊精的组合。
25.如权利要求21所述的方法,其中类胡萝卜素选自虾青素、番茄红素、玉米黄素、β-胡萝卜素、叶黄素以及它们的混合物。
26.如权利要求21所述的方法,其中其它营养组分是进行共同给药的,所述其它营养成分选自蜂蜡、维生素A、维生素E、D-柠檬烯以及它们的混合物。
27.如权利要求21所述的方法,其中所述类胡萝卜素、环糊精及鱼油以单一剂型给药。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72405105P | 2005-10-05 | 2005-10-05 | |
US60/724,051 | 2005-10-05 | ||
US11/538,766 | 2006-10-04 | ||
US11/538,766 US7781572B2 (en) | 2005-10-05 | 2006-10-04 | Nanosized carotenoid cyclodextrin complexes |
PCT/US2006/039383 WO2007044659A2 (en) | 2005-10-05 | 2006-10-05 | Nanosized carotenoid cyclodextrin complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101505596A CN101505596A (zh) | 2009-08-12 |
CN101505596B true CN101505596B (zh) | 2012-07-18 |
Family
ID=37943453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800372474A Active CN101505596B (zh) | 2005-10-05 | 2006-10-05 | 纳米级类胡萝卜素环糊精复合物 |
Country Status (7)
Country | Link |
---|---|
US (5) | US7781572B2 (zh) |
EP (1) | EP1931361A4 (zh) |
JP (1) | JP5106402B2 (zh) |
KR (1) | KR101255874B1 (zh) |
CN (1) | CN101505596B (zh) |
TW (2) | TWI514970B (zh) |
WO (1) | WO2007044659A2 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7781572B2 (en) * | 2005-10-05 | 2010-08-24 | Nse Products, Inc. | Nanosized carotenoid cyclodextrin complexes |
ES2317786B1 (es) * | 2007-07-31 | 2010-02-16 | Consejo Superior De Investigaciones Cientificas | Agregado o complejo molecular carotenoide soluble, procedimiento de obtencion y sus aplicaciones. |
NO20081487L (no) | 2008-03-27 | 2009-09-28 | Smartfish As | Helsefremmende drikk |
GB0817701D0 (en) * | 2008-09-26 | 2008-11-05 | Omegatri As | Krill oil powder and krill oil tablets |
US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
US20130011469A1 (en) | 2009-07-23 | 2013-01-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Krill oil and carotenoid composition, associated method and delivery system |
US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
US20110144200A1 (en) * | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
US8410079B2 (en) * | 2010-08-06 | 2013-04-02 | Island Kinetics | Chirally correct retinal cyclodextrin hemiacetals for clarifying skin complexion |
SG11201500379QA (en) * | 2012-07-19 | 2015-03-30 | Us Nutraceuticals Llc Dba Valensa Int | Krill oil and reacted astaxanthin composition and associated method |
AR095937A1 (es) | 2013-04-05 | 2015-11-25 | Acraf | Potenciador de la solubilidad en agua a base de glucógeno |
KR101468308B1 (ko) | 2013-05-31 | 2014-12-03 | 명지대학교 산학협력단 | 카로티노이드 나노입자의 제조방법 |
JP2015159801A (ja) * | 2014-02-28 | 2015-09-07 | サンデン商事株式会社 | γ−トコトリエノールにより酸化防止されたクリルオイルを含むサプリメント |
JP6299689B2 (ja) * | 2014-07-24 | 2018-03-28 | 三生医薬株式会社 | 生体吸収促進剤含有組成物 |
CN104784059A (zh) * | 2015-03-14 | 2015-07-22 | 吉林中粮生化有限公司 | 一种类胡萝卜素包合物和聚谷氨酸组合物及其用途 |
CN107158400A (zh) * | 2017-07-10 | 2017-09-15 | 北京素维生物科技有限公司 | 眼睛营养强化剂溶液组合物及其制备方法 |
WO2021046459A1 (en) * | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting heart/brain axis |
WO2021046450A1 (en) | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of supplementation affecting the endocannabinoid system |
AU2020343016A1 (en) | 2019-09-04 | 2022-04-14 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting mood and focus in children |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189149A (en) * | 1990-08-09 | 1993-02-23 | Staroil Limited | Method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes |
CN1638806A (zh) * | 2001-12-21 | 2005-07-13 | 奇斯药制品公司 | 通过微波处理制备非甾体抗炎药与β-环糊精包含物的方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834445A (en) | 1989-08-11 | 1998-11-10 | Sikorski; Christopher | Process for preparing decolorized carotenoid-cyclodextrin complexes |
US5221735A (en) | 1991-02-25 | 1993-06-22 | Hoffmann-La Roche Inc. | Cyclodextrin-polyene inclusion complexes |
US5321014A (en) | 1991-06-28 | 1994-06-14 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells |
WO1996040262A2 (en) | 1995-06-07 | 1996-12-19 | The Procter & Gamble Company | Process for preparing encapsulated water soluble beta-carotene |
IL121112A (en) * | 1997-06-19 | 2005-11-20 | Lycored Natural Prod Ind Ltd | Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
DE19941769A1 (de) | 1999-09-02 | 2001-03-08 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Biotin und/oder Biotinderivaten und Cyclodextrinen und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
DE10035513A1 (de) | 2000-07-21 | 2002-01-31 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
US6884885B2 (en) | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
US6695453B2 (en) * | 2001-02-09 | 2004-02-24 | Avery Dennison Corporation | Rear projection screens and light filters with conformable coatings and methods of making the same |
FR2823207B1 (fr) | 2001-04-10 | 2004-12-03 | Pf Medicament | Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies |
NZ536267A (en) * | 2002-04-10 | 2007-06-29 | Fred H Miller | Multi-phase, multi-compartment and multi-ingredient capsular system |
CN1656178A (zh) * | 2002-05-30 | 2005-08-17 | 化尔氏制药研究公司 | 油溶性色素合成物 |
WO2004005353A1 (en) | 2002-07-04 | 2004-01-15 | Poltec As | Complexes of cyclodextrins and carotenoids |
US20040109920A1 (en) * | 2002-12-04 | 2004-06-10 | Bioactives Llc | Coated carotenoid cyclodextrin complexes |
WO2005075613A1 (en) * | 2004-02-06 | 2005-08-18 | Adrien Beaudoin | Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof |
CN1917772A (zh) | 2004-02-23 | 2007-02-21 | 得克萨斯A&M大学系统 | 抗氧化组合物及其使用方法 |
US8067045B2 (en) * | 2005-03-03 | 2011-11-29 | Pharmanex, Llc | Nutritional formulations and associated methods |
US7781572B2 (en) * | 2005-10-05 | 2010-08-24 | Nse Products, Inc. | Nanosized carotenoid cyclodextrin complexes |
-
2006
- 2006-10-04 US US11/538,766 patent/US7781572B2/en active Active
- 2006-10-05 CN CN2006800372474A patent/CN101505596B/zh active Active
- 2006-10-05 WO PCT/US2006/039383 patent/WO2007044659A2/en active Application Filing
- 2006-10-05 TW TW103125072A patent/TWI514970B/zh active
- 2006-10-05 JP JP2008534755A patent/JP5106402B2/ja active Active
- 2006-10-05 EP EP06836231A patent/EP1931361A4/en not_active Withdrawn
- 2006-10-05 KR KR1020087008961A patent/KR101255874B1/ko active IP Right Grant
- 2006-10-05 TW TW095137067A patent/TWI462740B/zh active
-
2010
- 2010-05-20 US US12/784,387 patent/US20110129562A1/en not_active Abandoned
-
2016
- 2016-03-01 US US15/058,046 patent/US20170021035A1/en not_active Abandoned
-
2018
- 2018-04-16 US US15/954,464 patent/US20190111020A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/216,506 patent/US20210322371A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189149A (en) * | 1990-08-09 | 1993-02-23 | Staroil Limited | Method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes |
CN1638806A (zh) * | 2001-12-21 | 2005-07-13 | 奇斯药制品公司 | 通过微波处理制备非甾体抗炎药与β-环糊精包含物的方法 |
Non-Patent Citations (1)
Title |
---|
ROBERT L. ROSENTHAL, MD.Effectiveness of altering serum cholesterol levels..《Baylor University Medical Proceedings》.2000,第13卷(第4期),351-355. * |
Also Published As
Publication number | Publication date |
---|---|
TW200800229A (en) | 2008-01-01 |
WO2007044659A2 (en) | 2007-04-19 |
US7781572B2 (en) | 2010-08-24 |
US20070191307A1 (en) | 2007-08-16 |
TW201440665A (zh) | 2014-11-01 |
CN101505596A (zh) | 2009-08-12 |
US20190111020A1 (en) | 2019-04-18 |
US20110129562A1 (en) | 2011-06-02 |
KR101255874B1 (ko) | 2013-04-17 |
KR20080055920A (ko) | 2008-06-19 |
US20170021035A1 (en) | 2017-01-26 |
EP1931361A2 (en) | 2008-06-18 |
JP2009524576A (ja) | 2009-07-02 |
US20210322371A1 (en) | 2021-10-21 |
TWI514970B (zh) | 2016-01-01 |
WO2007044659A3 (en) | 2009-04-30 |
TWI462740B (zh) | 2014-12-01 |
JP5106402B2 (ja) | 2012-12-26 |
EP1931361A4 (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101505596B (zh) | 纳米级类胡萝卜素环糊精复合物 | |
CN101291598B (zh) | 具有高生物利用度的脂溶性活性成分的新颖制剂 | |
JP5596704B2 (ja) | フコキサンチン抽出物を含有する組成物 | |
WO2005110375A1 (en) | Nutritional supplement for treatment of ocular diseases | |
TWI351277B (en) | Compositions containing reduced coenzyme q10 and c | |
JP2009538353A (ja) | 眼の健康を増進するための組成物 | |
JP4859006B2 (ja) | 安定なアスタキサンチン−シクロデキストリン包接化合物及びその製造方法、並びに該包接化合物を含有する液剤、飲食物、飼料、医薬品及び化粧品 | |
Arumugam et al. | Fruits and vegetables as Superfoods: Scope and demand | |
Kakkar et al. | Utilizing fruits and vegetables waste as functional food: A review | |
JP2003304845A (ja) | 飲料または食品 | |
Benadé | Red Palm Oil Carotenoids | |
CN101528245A (zh) | 用于改善皮肤状态的组合物 | |
WO2021178291A1 (en) | Undenatured type ii collagen in food and beverage applications and uses thereof | |
KR101795692B1 (ko) | 황반색소 밀도유지용 복합제제의 제조방법 | |
JP2003304846A (ja) | 飲料または食品 | |
KR20040063616A (ko) | 다이어트 식품용 조제 | |
Naguib | Carotenoids come of age | |
KR20230139411A (ko) | 시트러스 계열 과일 추출물을 유효성분으로 포함하는 항균용 조성물 | |
JP2012077087A (ja) | 安定なアスタキサンチンとγ−シクロデキストリンとの包接化合物、並びにそれを含む飲食物、飼料及び医薬品 | |
JPWO2017195504A1 (ja) | 血中カロテノイドバランス改善剤 | |
CN114747704A (zh) | 护眼美容养颜饮料及其制备方法 | |
WO2004010790A1 (en) | Sweet products with flavin content and methods of producing thereof | |
CN108157534A (zh) | 一种具有抗氧化作用的保健型食用油 | |
Pattan et al. | An Overview of Lycopene as an Anti Oxidants & the Development of Extraction Procedure of Lycopene from Regional Guava Fruit. | |
CN104997031A (zh) | 一种天然维生素c的复合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |